The PG500 series: Novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 276-283

  Dredge, K ^a   Hammond, E ^a   Davis, K ^a   Li, C P ^a   Liu, L ^a,b   Johnstone, K ^a   Handley, P ^a   Wimmer, N ^a   Gonda, T J ^b   Gautam, A ^a   Ferro, V ^a,c   Bytheway, I ^a  

^a Progen Pharmaceuticals Limited   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Angiogenesis; Cancer therapy; Heparan sulfate; Heparanase

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; HEPARANASE; PG 517; PG 518; PG 536; PG 537; PG 545; PG 546; PG 547; PG 554; PG 561; PG 562; PI 88; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; LUNG METASTASIS; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952239575     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9245-5     Document Type: Article

References (22)

1. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249 257 10.1038/35025220 10.1038/35025220 1:CAS:528:DC%2BD3cXmvVSls74%3D 11001068
2. G Bergers LE Benjamin 2003 Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 401 410 10.1038/nrc1093 10.1038/nrc1093 1:CAS:528: DC%2BD3sXktFOnsb8%3D 12778130 (Pubitemid 37328844)
3. RS Herbst 2006 Therapeutic options to target angiogenesis in human malignancies Expert Opin Emerg Drugs 11 635 650 10.1517/14728214.11.4.635 10.1517/14728214.11.4.635 1:CAS:528:DC%2BD28XhtFWltbfL 17064223 (Pubitemid 44735590)
4. R Sasisekharan Z Shriver G Venkataraman, et al. 2002 Roles of heparan-sulphate glycosaminoglycans in cancer Nat Rev Cancer 2 521 528 10.1038/nrc842 10.1038/nrc842 1:CAS:528:DC%2BD38XkvFKltLY%3D 12094238
5. Y Wegrowski FX Maquart 2004 Involvement of stromal proteoglycans in tumour progression Crit Rev Oncol Hematol 49 259 268 10.1016/j.critrevonc.2003. 10.005 10.1016/j.critrevonc.2003.10.005 15036265 (Pubitemid 38251357)
6. R Lever CP Page 2002 Novel drug development opportunities for heparin Nat Rev Drug Discov 1 140 148 10.1038/nrd724 10.1038/nrd724 1:CAS:528: DC%2BD38Xhs1aksLc%3D 12120095 (Pubitemid 41646521)
7. M Presta D Leali H Stabile, et al. 2003 Heparin derivatives as angiogenesis inhibitors Curr Pharm Des 9 553 566 10.2174/1381612033391379 10.2174/1381612033391379 1:CAS:528:DC%2BD3sXhsVOhs70%3D 12570803 (Pubitemid 36221723)
8. T Karoli L Liu JK Fairweather, et al. 2005 Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88) J Med Chem 48 8229 8236 10.1021/jm050618p 10.1021/jm050618p 1:CAS:528:DC%2BD2MXht1WltLzP 16366604 (Pubitemid 43032531)
9. A Zetser Y Bashenko E Edovitsky, et al. 2006 Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation Cancer Res 66 1455 1463 10.1158/0008-5472.CAN-05-1811 10.1158/0008-5472.CAN-05-1811 1:CAS:528:DC%2BD28XpsVehuw%3D%3D 16452201 (Pubitemid 43259926)
10. V Cohen-Kaplan I Naroditsky A Zetser, et al. 2008 Heparanase induces VEGF C and facilitates tumor lymphangiogenesis Int J Cancer 123 2566 2573 10.1002/ijc.23898 10.1002/ijc.23898 1:CAS:528:DC%2BD1cXhtlyru7vE 18798279
11. I Vlodavsky M Elkin G Abboud-Jarrous, et al. 2008 Heparanase: one molecule with multiple functions in cancer progression Connect Tissue Res 49 207 210 10.1080/03008200802143281 10.1080/03008200802143281 1:CAS:528: DC%2BD1cXptVKlsbY%3D 18661344
12. S Cochran C Li JK Fairweather, et al. 2003 Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance J Med Chem 46 4601 4608 10.1021/jm030180y 10.1021/jm030180y 1:CAS:528: DC%2BD3sXnt1Ogtrc%3D 14521421 (Pubitemid 37238760)
13. Cochran S, Li CP, Ferro V (2008). A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconjuate J. doi: 10.1007/s10719-008-9210-0
14. A Bisio A Mantegazza E Urso, et al. 2007 High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase Semin Thromb Hemost 33 488 495 10.1055/s-2007-982079 10.1055/s-2007-982079 1:CAS:528:DC%2BD2sXptlKnsL0%3D 17629845 (Pubitemid 47105738)
15. E McKenzie K Young M Hircock, et al. 2003 Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells Biochem J 373 423 435 10.1042/BJ20030318 10.1042/BJ20030318 1:CAS:528:DC%2BD3sXmsFGrt7k%3D 12713442 (Pubitemid 36897845)
16. Y Cheng WH Prusoff 1973 Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem Pharmacol 22 3099 3108 10.1016/0006-2952(73) 90196-2 10.1016/0006-2952(73)90196-2 1:CAS:528:DyaE2cXhtVGgs7c%3D 4202581
17. RF Nicosia A Ottinetti 1990 Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot In Vitro Cell Dev Biol 26 119 128 10.1007/BF02624102 10.1007/BF02624102 1:STN:280:DyaK3c7os1Khsg%3D%3D 1690206
18. J-K Min K-Y Han E-C Kim, et al. 2004 Capsaicin Inhibits in Vitro and in Vivo Angiogenesis Cancer Res 64 644 651 10.1158/0008-5472.CAN-03-3250 10.1158/0008-5472.CAN-03-3250 1:CAS:528:DC%2BD2cXmsVahsg%3D%3D 14744780 (Pubitemid 38120905)
19. R Auerbach R Lewis B Shinners, et al. 2003 Angiogenesis assays: a critical overview Clin Chem 49 32 40 10.1373/49.1.32 10.1373/49.1.32 1:CAS:528:DC%2BD3sXktFGntw%3D%3D 12507958 (Pubitemid 36078551)
20. V Ferro K Dredge L Liu, et al. 2007 PI-88 and novel heparan sulfate mimetics inhibit angiogenesis Semin Thromb Hemost 33 557 568 10.1055/s-2007-982088 10.1055/s-2007-982088 1:CAS:528:DC%2BD2sXptlKnsb0%3D 17629854 (Pubitemid 47105747)
21. JML Ebos CR Lee W Cruz-Munoz, et al. 2009 Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 232 239 10.1016/j.ccr.2009.01.021 10.1016/j.ccr.2009.01.021 1:CAS:528:DC%2BD1MXltFSmtbc%3D 19249681
22. M Paez-Ribes E Allen J Hudock, et al. 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 220 231 10.1016/j.ccr.2009.01.027 10.1016/j.ccr.2009. 01.027 1:CAS:528:DC%2BD1MXltFSmtbY%3D 19249680